RUCONEST®
C1 esterase inhibitor (recombinant)

Are your swells stopped with just one dose?

It may be time to rethink your acute therapy.

If you answer yes to any of the following questions, it's time to rethink your acute treatment

1. Have I had to use more than one injection to treat painful swells?
2. Have I missed work or activities because I have needed to a treat a swell with more than one injection?

WHAT IS RUCONEST?

RUCONEST is an injectable prescription medicine that is used to treat swelling and/or painful attacks due to hereditary angioedema (HAE) in adult and adolescent patients over the age of 12.

Important Safety Information

Do not use RUCONEST if you have experienced life-threatening immediate hypersensitivity reactions, including anaphylaxis, to RUCONEST or to any other C1 esterase inhibitor (C1-INH) product. Call your healthcare professional or the emergency department right away if you experience: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling, faintness, rash or hives. A serious side effect of life-threatening hypersensitivity (anaphylaxis) was reported in a clinical study.

RUCONEST®
C1 esterase inhibitor (recombinant)

RUCONEST can help you get back to things that matter

1

JUST ONE DOSE
97% of acute attacks needed **just 1 dose of RUCONEST**[1*]

3 DAYS

DURABLE RESPONSE
RUCONEST stopped **93%** of attacks **for at least 3 days**[2†]

85%

CONFIDENT
85% of patients were confident in **self-injecting** RUCONEST(n=601)[3‡]

- **~ 9 of 10 patients** achieved symptom relief with **just one dose** of RUCONEST at 50 U/kg (n=44) in the primary clinical study[1]
- In the primary clinical study, patients saw **symptom relief in 90 minutes** vs 152 minutes with placebo[1]

* 50 U/kg (max 4200 U) in clinical studies (open-label extension phase, n=44 ([170 attacks]).
† Based on a post hoc analysis of pooled data from the randomized controlled study and open-label extension phases of 2 studies involving 127 patients aged ≥13 years who were treated with RUCONEST 50 U/kg (max 4200 U) for acute attacks of HAE. Data for 72 hours were available for 68 of 127 patients, (280 attacks).[1]
‡ Data from 601 patients using RUCONEST show that ~85% of patients trained feel somewhat confident, mostly confident, or extremely confident on a Likert scale from 1-5 in terms of their ability to self-infuse.

Important Safety Information (cont.)

Do not use RUCONEST if you have a known or suspected allergy to rabbits or rabbit-derived products. Tell your healthcare provider about all your medical conditions, including if you have a known allergy to rabbits.

Before starting RUCONEST, tell your healthcare provider about any other medications you are taking, as some medications, such as birth control pills and certain androgens, can increase risk of clotting problems. Blood clots have occurred in patients receiving plasma-derived C1-INH product. Also tell your healthcare provider if you are pregnant, breastfeeding, or planning to do so.

The most common side effects patients experienced during clinical studies include headache, nausea and diarrhea. These are not all the possible side effects of RUCONEST. Tell your healthcare provider about any side effect that bothers you or does not go away. You can also report negative side effects to Pharming Medical Affairs at (800) 930-5221, or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

If symptoms persist, a second dose of RUCONEST may be taken at your recommended dose. Do not take more than two doses within 24 hours.

For more information, please see the full accompanying Prescribing Information, including Patient Product Information, or go to www.RUCONEST.com.

References: 1. Ruconest. Prescribing Information. Pharming Healthcare, Inc; 2020. **2.** Bernstein JA, Relan A, Harper JR, Reidl M. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. *Ann Allergy Asthma Immunol.* 2017;118(4):452-455. **3.** Data on file. 2019.

Pharming